Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Nefiracetam Therapy of Alzheimer's Type Dementia
Authors not listed
National Institute of Neurological Disorders and Stroke (NINDS) · 1999
Abstract
Some of the thinking difficulties of Alzheimer's patients may be due to a deficiency in a brain chemical called acetylcholine, which helps transmit messages between nerve cells. Nefiracetam is a new drug that stimulates acetylcholine. This study will test whether Nefiracetam can safely improve memory, thinking and activities of daily living in patients with mild to moderate intellectual impairment due to Alzheimer's disease.
Patients in the study must have a caregiver and designated representative. Candidates will be given a medical history and physical examination that includes a complete neurologic and neuropsychologic evaluation, blood tests, and an electrocardiogram. A chest X ray and magnetic resonance imaging (MRI) test will be done on patients who have not had these tests within the previous two years. During the 20-week study, each patient will take three pills twice a day for twenty weeks of either Nefiracetame or placebo (sugar pill). Neither the patients nor the doctors will know which patients are getting the drug and which are getting the placebo. Blood and urine tests will be done frequently throughout the study. Patients will be asked to have a spinal tap (on a voluntary basis) to measure the levels of drug in the spinal fluid, and a PET scan (a brain imaging test).
At the end of the study, patients who feel they are doing well with no side effects from the drug (or placebo) may be given the option of continuing treatment for another seven months.
Animal studies showed that Nefiracetam improved learning impairment and memory in rats with dementia. In a small study of humans, about one-fourth of patients who were given a low dose of the drug had improved intellectual function, and about one-half who received a higher dose improved.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-10 MST
Cite this
APA
Anonymous. (1999). Nefiracetam Therapy of Alzheimer's Type Dementia. <em>National Institute of Neurological Disorders and Stroke (NINDS)</em>. https://clinicaltrials.gov/study/NCT00001933
Vancouver
Anonymous. Nefiracetam Therapy of Alzheimer's Type Dementia. National Institute of Neurological Disorders and Stroke (NINDS). 1999.
BibTeX
@misc{anon1999Nefira,
title = {Nefiracetam Therapy of Alzheimer's Type Dementia},
author = {Anonymous},
journal = {National Institute of Neurological Disorders and Stroke (NINDS)},
year = {1999},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
University of Wisconsin, Madison 2009
Open access · US-GOV
Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's
Massachusetts General Hospital 2025
Open access · US-GOV
Grit Against Cognitive Decline in Aging and Preclinical Alzheimer's Disease
Patrick Lao 2017
Open access · US-GOV
Imaging Tau in Alzheimer's Disease and Normal Aging With 18F-MK-6240
William Charles Kreisl 2016
Open access · US-GOV
Imaging Tau in Alzheimer's Disease and Normal Aging
National Institute on Aging (NIA) 2010
Open access · US-GOV
A Pilot Study of Exendin-4 in Alzheimer s Disease
Healthy ageing and longevity 2017
Citation only